In the agreed position, they recommend prophylaxis against Pneumocystis jirovecii in all patients for the entire duration of treatment with the anti-CD38 if in association with a high-dose steroid, while fluoroquinolone prophylaxis is encouraged during front-line therapy including daratumumab only in patients at high risk for infection identified on the basis of past medical history, age, and tumor burden. This evidence concerns the gene CD38 and neoplasm.